CryoPort, Inc. (NASDAQ:CYRX) Receives $12.94 Average Target Price from Brokerages

Shares of CryoPort, Inc. (NASDAQ:CYRX) have received a consensus rating of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $12.9444.

A number of research analysts have issued reports on the company. Needham & Company LLC upped their price objective on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Finally, Wall Street Zen lowered shares of CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th.

CryoPort Stock Performance

Shares of NASDAQ CYRX opened at $8.41 on Monday. The stock has a market cap of $419.32 million, a price-to-earnings ratio of 6.37 and a beta of 1.69. CryoPort has a fifty-two week low of $4.63 and a fifty-two week high of $11.45. The firm’s 50-day simple moving average is $8.90 and its 200 day simple moving average is $9.32.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. The company had revenue of $45.45 million during the quarter, compared to analysts’ expectations of $42.92 million. On average, sell-side analysts predict that CryoPort will post -0.99 EPS for the current year.

Insider Buying and Selling

In related news, CFO Robert Stefanovich sold 38,700 shares of CryoPort stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $7.76, for a total value of $300,312.00. Following the completion of the sale, the chief financial officer owned 255,701 shares of the company’s stock, valued at approximately $1,984,239.76. This trade represents a 13.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 7,918 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the sale, the chief executive officer owned 1,054,501 shares in the company, valued at $8,436,008. This represents a 0.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 59,939 shares of company stock valued at $471,183. 10.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On CryoPort

Institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. lifted its stake in CryoPort by 37.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after purchasing an additional 408,263 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of CryoPort by 663.2% in the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock worth $1,207,000 after purchasing an additional 110,602 shares in the last quarter. Bullseye Asset Management LLC increased its position in shares of CryoPort by 23.0% during the 2nd quarter. Bullseye Asset Management LLC now owns 260,168 shares of the company’s stock valued at $1,941,000 after purchasing an additional 48,605 shares during the last quarter. Thematics Asset Management raised its holdings in shares of CryoPort by 12.8% during the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock valued at $14,285,000 after buying an additional 216,937 shares in the last quarter. Finally, Mak Capital One LLC purchased a new position in shares of CryoPort during the 3rd quarter valued at about $7,756,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.